ReviewNature reviews. Neurology2011
How can we improve clinical trials in amyotrophic lateral sclerosis?
Review in Nature reviews. Neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Methodological Quality of Clinical Trials in Amyotrophic Lateral Sclerosis: A Systematic Review.Journal of neuromuscular diseases · 2024Pooled it
- Ageing, Neurodegeneration and the Endocannabinoid System.Current topics in behavioral neurosciences · 2026Review
- Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery.International journal of molecular sciences · 2021Review
- Applications of machine learning to diagnosis and treatment of neurodegenerative diseases.Nature reviews. Neurology · 2020Review
- Brain Stimulation as a Therapeutic Tool in Amyotrophic Lateral Sclerosis: Current Status and Interaction With Mechanisms of Altered Cortical Excitability.Frontiers in neurology · 2020Review
- Insights into Amyotrophic Lateral Sclerosis from a Machine Learning Perspective.Journal of clinical medicine · 2019Article
- The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes.British journal of pharmacology · 2019Review
- Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.Neurology · 2019Article
- Modeling hallmark pathology using motor neurons derived from the family and sporadic amyotrophic lateral sclerosis patient-specific iPS cells.Stem cell research & therapy · 2018Article
- Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis.Clinical epidemiology · 2018Article
- Studying human disease using human neurons.Brain research · 2017Review
- Central Nervous System-Peripheral Immune System Dialogue in Neurological Disorders: Possible Application of Neuroimmunology in Urology.International neurourology journal · 2016Review
- Advances in Stem Cell Research- A Ray of Hope in Better Diagnosis and Prognosis in Neurodegenerative Diseases.Frontiers in molecular biosciences · 2016Review
- Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.Acta neuropathologica · 2015Article
- Induced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous System.Stem cells and development · 2015Review
- Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration.Frontiers in cellular neuroscience · 2015Article
- Moving forward in clinical trials for ALS: motor neurons lead the way please.Drug discovery today · 2014Review
- Outcome measures in amyotrophic lateral sclerosis clinical trials.Clinical investigation · 2014Article
- Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials.Aging and disease · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the approval of riluzole for the treatment of amyotrophic lateral sclerosis (ALS) 17 years ago, more than 30 large clinical trials have been conducted, but none has proved successful. The failure to translate positive preclinical results into the clinical setting raises questions about the validity of the rodent model that is used to study ALS, and about the quality of both preclinical and clinical studies. However, the greatest challenge is the disease itself as, with rare exceptions, the causes are unknown. In this Perspectives article, we highlight key issues related to the pathophysiology, preclinical studies and clinical trials that should be addressed in the future. These areas include the relationships between different disease mechanisms, the challenges presented by the heterogeneity of the disease, and the need for early intervention, optimal dose selection and effective biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.